Asia-Pacific schizophrenia drugs market is projected to grow at a significant CAGR of 3.6% during the forecast period (2020-2026). In Asia-Pacific, the schizophrenia has a high prevalence in South Asian countries as compared to the rest of the region. According to the Progress in Mind, there are significantly different medication patterns preferred across South Asian countries.
- 42% of patients were prescribed more than 1 antipsychotic; however, polypharmacy rates ranged from 59% in Vietnam to 22% in Myanmar.
- Anxiolytics (Pakistan 56% compared to Myanmar 9%)
- Hypnotics (Japan 61% compared to Sri Lanka and Myanmar 0%)
- Anti-Parkinsonian drugs (Bangladesh 88% compared to Vietnam 11%)
The presence of huge population and gender inequality in the South Asian economies, such as Pakistan and India, has been the major factor for the rising demand for schizophrenia drugs in these economies. Along with this, the increasing awareness about mental health in the emerging South Asian economies, such as India and Vietnam, the schizophrenia drug industry is continuously increasing and driving the Asia-Pacific schizophrenia drug market. There are several mental health organizations and hospitals being established in the last decade and the trend is expected to continue during the forecast period.
OMR Global Recently Published Report on: https://www.omrglobal.com/industry-reports/asia-pacific-schizophrenia-drugs-market
Asia-Pacific Schizophrenia Drugs Market – Segmentation
By Therapeutic Class
- Second Generation Antipsychotics
- Third Generation Antipsychotics
- Others (First Generation Antipsychotics)
By Treatment
- Oral
- Injectables
Asia-Pacific Schizophrenia Drugs Market – Segmentation by Geography
- China
- India
- Japan
- Rest of Asia-Pacific
To Learn More About this Report Request a Free Sample Copy @ https://www.omrglobal.com/request-sample/asia-pacific-schizophrenia-drugs-market
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
